AU2509201A - Screening method for compounds capable of modularing egr-1-regulated expression - Google Patents

Screening method for compounds capable of modularing egr-1-regulated expression

Info

Publication number
AU2509201A
AU2509201A AU25092/01A AU2509201A AU2509201A AU 2509201 A AU2509201 A AU 2509201A AU 25092/01 A AU25092/01 A AU 25092/01A AU 2509201 A AU2509201 A AU 2509201A AU 2509201 A AU2509201 A AU 2509201A
Authority
AU
Australia
Prior art keywords
modularing
egr
screening method
compounds capable
regulated expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU25092/01A
Inventor
Martin Braddock
Callum Jeffrey Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2509201A publication Critical patent/AU2509201A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
AU25092/01A 1999-12-01 2000-11-30 Screening method for compounds capable of modularing egr-1-regulated expression Abandoned AU2509201A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9928430 1999-12-01
GBGB9928430.9A GB9928430D0 (en) 1999-12-01 1999-12-01 Screening
PCT/EP2000/011997 WO2001040460A1 (en) 1999-12-01 2000-11-30 Screening method for compounds capable of modularing egr-1-regulated expression

Publications (1)

Publication Number Publication Date
AU2509201A true AU2509201A (en) 2001-06-12

Family

ID=10865529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25092/01A Abandoned AU2509201A (en) 1999-12-01 2000-11-30 Screening method for compounds capable of modularing egr-1-regulated expression

Country Status (5)

Country Link
EP (1) EP1244786A1 (en)
JP (1) JP2003515339A (en)
AU (1) AU2509201A (en)
GB (1) GB9928430D0 (en)
WO (1) WO2001040460A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106488A2 (en) * 2006-03-13 2007-09-20 Wyeth Modulators of gluconeogenesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
AUPN855496A0 (en) * 1996-03-07 1996-04-04 Unisearch Limited Prevention of proliferation of vascular cells
DE69910202T2 (en) * 1998-06-02 2004-06-17 Glaxo Group Ltd., Greenford EGR-1 for the manufacture of a medicament for the treatment of wounds
JP2002520020A (en) * 1998-07-11 2002-07-09 グラクソ グループ リミテッド Use of NAB1 and NAB2 as drugs

Also Published As

Publication number Publication date
JP2003515339A (en) 2003-05-07
GB9928430D0 (en) 2000-01-26
EP1244786A1 (en) 2002-10-02
WO2001040460A8 (en) 2001-11-08
WO2001040460A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
AU2557500A (en) Methods of making compounds
AU1035199A (en) Method for modification of cellulose
AU775075C (en) Method for separating analogous organic compounds
AU4277700A (en) Method for removal of sic
AU7902400A (en) Method for the preparation of 5-carboxyphthalide
AU1133201A (en) Method for selecting drilling parameters
AU1036601A (en) Method of screening for inhibitors of asp1
AU2964500A (en) Method of micro-fabrication
AU7715300A (en) Method of preventing osteoporosis
AU2376001A (en) Method for the manufacture of olefins
AU1788800A (en) Derivative of paroxetine
AU1553101A (en) Screening method
AU3005500A (en) Methods of screening for antiviral compounds
AU9363698A (en) Method for preparing bicycloheptan-amine compounds
AU2222499A (en) Method of synthesis of derivatives of aloesin
AU6429000A (en) Screening method
AU2002247215A1 (en) Method for screening compounds
AU3984700A (en) Compound screening methods
AU5310600A (en) Process for deacylation of lipodepsipeptides
AU1037901A (en) Process for the preparation of paroxetine
AU1810399A (en) Method for synthesizing
AU2001230365A1 (en) Method of screening compounds for biological activity
AU7901000A (en) Method for modifying coating materials
AU7269600A (en) A method of screening for substances acting on MSK1
AU2509201A (en) Screening method for compounds capable of modularing egr-1-regulated expression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 16, NO 11, PAGE(S) 2339-2354 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 47154/00, 47949/00, 51117/00, 74220/00, 20262/01, 20270/01, 25092/01, 40590/01, 42491/01, 42502/01, 46799/01, 48212/01, 48676/01, 50178/01, 50340/01, 50629/01, 55047/01, 56835/01, 57646/01, 60122/01, 62207/01 AND 68757/01

MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase